A Phase II Trial of Immunotherapy with MEDI4736 with Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase II Trial of Immunotherapy with MEDI4736 with Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.